Per Karlsson1, Bernard F Cole2, Karen N Price3, Richard D Gelber4, Alan S Coates5, Aron Goldhirsch6, Monica Castiglione7, Marco Colleoni8, Günther Gruber9. 1. Department of Oncology, Institute of Clinical Sciences, Sahgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden. Electronic address: per.karlsson@oncology.gu.se. 2. Department of Mathematics and Statistics, University of Vermont, Burlington, Vermont. 3. International Breast Cancer Study Group Statistical Center, Frontier Science and Technology Research Foundation, Boston, Massachusetts. 4. International Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Frontier Science and Technology Research Foundation, Harvard T. F. Chan School of Public Health, Boston, Massachusetts. 5. International Breast Cancer Study Group and University of Sydney, Sydney, Australia. 6. Senior Consultant Breast Cancer, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy. 7. International Breast Cancer Study Group, Bern, Switzerland. 8. Division of Medical Senology, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy. 9. Institute of Radiotherapy, Klinik Hirslanden, Zürich, Switzerland.
Abstract
PURPOSE: To update the previous report from 2 randomized clinical trials, now with a median follow-up of 16 years, to analyze the effect of radiation therapy timing on local failure and disease-free survival. PATIENTS AND METHODS: From July 1986 to April 1993, International Breast Cancer Study Group trial VI randomly assigned 1475 pre-/perimenopausal women with node-positive breast cancer toreceive 3 or 6 cycles of initial chemotherapy (CT). International Breast Cancer Study Group trial VII randomly assigned 1212 postmenopausal women with node-positive breast cancer to receivetamoxifen for 5 years, or tamoxifen for 5 years with 3 early cycles of initial CT. For patients who received breast-conserving surgery (BCS), radiation therapy (RT) was delayed until initial CT was completed; 4 or 7 months after BCS for trial VI and 2 or 4 months for trial VII. We compared RT timing groups among 433 patients on trial VI and 285 patients on trial VII who receivedBCS plus RT. Endpoints were local failure, regional/distant failure, and disease-free survival (DFS). RESULTS: Among pre-/perimenopausal patients there were no significant differences in disease-related outcomes. The 15-year DFS was 48.2% in the group allocated 3 months initial CT and 44.9% in the group allocated 6 months initial CT (hazard ratio [HR] 1.12; 95% confidence interval [CI] 0.87-1.45). Among postmenopausal patients, the 15-year DFS was 46.1% in the no-initial-CT group and 43.3% in the group allocated 3 months initial CT (HR 1.11; 95% CI 0.82-1.51). Corresponding HRs for local failures were 0.94 (95% CI 0.61-1.46) in trial VI and 1.51 (95% CI 0.77-2.97) in trial VII. For regional/distant failures, the respective HRs were 1.15 (95% CI 0.80-1.63) and 1.08 (95% CI 0.69-1.68). CONCLUSIONS: This study confirms that, after more than 15 years of follow-up, it is reasonable to delay radiation therapy until after the completion of standard CT.
RCT Entities:
PURPOSE: To update the previous report from 2 randomized clinical trials, now with a median follow-up of 16 years, to analyze the effect of radiation therapy timing on local failure and disease-free survival. PATIENTS AND METHODS: From July 1986 to April 1993, International Breast Cancer Study Group trial VI randomly assigned 1475 pre-/perimenopausal women with node-positive breast cancer to receive 3 or 6 cycles of initial chemotherapy (CT). International Breast Cancer Study Group trial VII randomly assigned 1212 postmenopausal women with node-positive breast cancer to receive tamoxifen for 5 years, or tamoxifen for 5 years with 3 early cycles of initial CT. For patients who received breast-conserving surgery (BCS), radiation therapy (RT) was delayed until initial CT was completed; 4 or 7 months after BCS for trial VI and 2 or 4 months for trial VII. We compared RT timing groups among 433 patients on trial VI and 285 patients on trial VII who received BCS plus RT. Endpoints were local failure, regional/distant failure, and disease-free survival (DFS). RESULTS: Among pre-/perimenopausal patients there were no significant differences in disease-related outcomes. The 15-year DFS was 48.2% in the group allocated 3 months initial CT and 44.9% in the group allocated 6 months initial CT (hazard ratio [HR] 1.12; 95% confidence interval [CI] 0.87-1.45). Among postmenopausal patients, the 15-year DFS was 46.1% in the no-initial-CT group and 43.3% in the group allocated 3 months initial CT (HR 1.11; 95% CI 0.82-1.51). Corresponding HRs for local failures were 0.94 (95% CI 0.61-1.46) in trial VI and 1.51 (95% CI 0.77-2.97) in trial VII. For regional/distant failures, the respective HRs were 1.15 (95% CI 0.80-1.63) and 1.08 (95% CI 0.69-1.68). CONCLUSIONS: This study confirms that, after more than 15 years of follow-up, it is reasonable to delay radiation therapy until after the completion of standard CT.
Authors: S Corradini; O M Niemoeller; M Niyazi; F Manapov; M Haerting; N Harbeck; C Belka; S Kahlert Journal: Strahlenther Onkol Date: 2014-02-07 Impact factor: 3.621
Authors: P J Froud; D Mates; J S Jackson; N Phillips; S Andersen; S M Jackson; C J Bryce; I A Olivotto Journal: Int J Radiat Oncol Biol Phys Date: 2000-01-15 Impact factor: 7.038
Authors: A Recht; S E Come; I C Henderson; R S Gelman; B Silver; D F Hayes; L N Shulman; J R Harris Journal: N Engl J Med Date: 1996-05-23 Impact factor: 91.245
Authors: S Darby; P McGale; C Correa; C Taylor; R Arriagada; M Clarke; D Cutter; C Davies; M Ewertz; J Godwin; R Gray; L Pierce; T Whelan; Y Wang; R Peto Journal: Lancet Date: 2011-10-19 Impact factor: 79.321
Authors: Marissa C van Maaren; Reini W Bretveld; Jan J Jobsen; Renske K Veenstra; Catharina Gm Groothuis-Oudshoorn; Hendrik Struikmans; John H Maduro; Luc Ja Strobbe; Philip Mp Poortmans; Sabine Siesling Journal: Br J Cancer Date: 2017-06-06 Impact factor: 7.640